by Chris Dokomajilar | Sep 15, 2023 | Analysis
Quarterly venture investment activity into neurology focused biopharma companies is back to pre-2020 level. This is no surprise given the investment slowdowns across all therapy area and broader life sciences. The drop seems to have stabilized however, and emerging...
by Chris Dokomajilar | Sep 8, 2023 | Analysis
We are tracking the biopharma R&D partnerships in neurology through the first half of 2023. Some notable licensing deals include Voyager’s partnership with Neurocrine, which secured an upfront payment of $175 million and the potential to achieve up to $4.2...
by Chris Dokomajilar | Aug 30, 2023 | Analysis, Funding
Biopharma IPO activity was still quiet through the second quarter 2023 with 3 companies going public on global exchanges for a total of $800 million. This follows 3 IPOs in the first quarter at $400 million. Among these IPOs, Laekna raised approximately $101 million...
by Chris Dokomajilar | Aug 21, 2023 | Analysis, Funding
The biopharmaceutical industry experienced a return of venture funding activity in the second quarter of 2023, driving therapeutic development and platform technology advancements. ElevateBio secured a noteworthy $401 million Series D financing to further develop...
by Chris Dokomajilar | Aug 14, 2023 | Analysis, Partnership Deals
Biopharma licensing activity in Q2 2023 was the lowest since 2019. Development and commercialization deals for the quarter came in at 110 deals for a total announced value of $28.2 billion with $1.2 billion in total upfront cash and equity. There were notable deals...
